Orally Disintegrating Tablet Market
Orally Disintegrating Tablet Market Study by Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, and Anti-Allergy Drugs from 2024 to 2034
Analysis of Orally Disintegrating Tablet Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Orally Disintegrating Tablet Market Outlook (2024 to 2034)
The global orally disintegrating tablet market has been estimated at a valuation of US$ 24.45 billion and is forecasted to rise at a CAGR of 11.5% to reach US$ 72.68 billion by the end of 2034.
The market is witnessing significant growth, aiding individuals of diverse ages in swallowing tablets effortlessly. Demand for orally disintegrating tablets (ODTs) is rising fast, especially among the elderly, due to muscle weakness that makes swallowing challenging. Increasing aging population is a key driver behind increased tablet sales. The rapid absorption of medication in the mouth accelerates entry into the bloodstream, rendering oral disintegrating tablets particularly suitable for conditions like neurological disorders, epilepsy, and sleep disorders.
Manufacturing oral disintegrating tablets involves loose compression tableting, enabling dissolution on the tongue rather than swallowing whole. This process benefits individuals with swallowing difficulties, contributing significantly to the market's growth.
Key Market Growth Drivers
- ODTs have the feature of rapid absorption, leading to a quick recovery process. More people are looking for ways to heal faster, attracting them toward using ODTs.
- As these medicines do not need to be swallowed, they eliminate the risk of choking or gagging, which is particularly beneficial for infants prone to choking on regular tablets.
- These tablets require no additional liquid for swallowing, making them convenient for consumption anywhere, anytime. With busy lifestyles, more people find these tablets facilitating easy medication intake.
- Patients with gastrointestinal issues opt for these tablets due to difficulties swallowing traditional ones, easing medication intake without needing assistance.
- Suppliers are focusing on aspects like aftertaste and mouthfeel to enhance the appeal of ODTs. With reduced bitterness and faster action, ODTs attract a broader patient base seeking improved taste and experience.
- Unlike traditional tablets requiring precise administration, ODTs offer ease and accuracy, promoting better patient adherence to treatment regimens.
- ODTs boast a longer shelf life, attributed to improved stability and manufacturing processes, providing ODT suppliers with a competitive edge over traditional tablets.
| Report Attribute | Detail |
|---|---|
| Orally Disintegrating Table Market Size (2024E) | US$ 24.45 Billion |
| Forecasted Market Value (2034F) | US$ 72.68 Billion |
| Global Market Growth Rate (2024 to 2034) | 11.5% CAGR |
| Canada Market Growth Rate (2024 to 2034) | 12.2% CAGR |
| Brazil Market Value (2034F) | US$ 1 Billion |
| North America Market Share (2024E) | 37.1% |
| Latin America Market Share (2034F) | 3.4% |
| Key Companies Profiled | Johnson & Johnson Services Inc; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; Eli Lily and Company; Dr. Reddy’s Laboratories Ltd; Mylan N.V.; Bausch Health; GlaxoSmithKline Plc; Merck & Co Inc.; AstraZeneca; Bayer AG; F Hoffman-La Roche Ltd. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why are Orally Disintegrating Tablets Preferred over Traditional Tablets and Capsules?
“Ability of ODTs to Dissolve Rapidly in Mouth Without Water Intake”
In recent years, orally disintegrating tablets (ODTs) have gained significant popularity as an alternative to traditional tablets and capsules due to improved patient compliance. These innovative tablets dissolve rapidly in the mouth, typically within minutes, and can be taken without the need for water, offering a convenient and accessible option for many individuals.
The challenge of swallowing traditional medications, especially for babies, young children, and the elderly, has been effectively addressed by the introduction of orally disintegrating tablets. To further enhance their performance and desirability, ongoing developments in this area have led to the introduction of various orally disintegrating pills with improved characteristics, including better taste and faster disintegration. These advancements are contributing to the expansion of the orally disintegrating tablet market size.
“Escalated Bioavailability Enhancing Effectiveness of Protein- and Peptide-Based Drugs”
Oral administration of medications often results in a significant reduction in the amount of drug reaching the bloodstream due to first-pass metabolism. Orally disintegrating tablets play a crucial role in overcoming this challenge by bypassing the first-pass metabolism issue, thereby enhancing the bioavailability of the administered medicines. This attribute is particularly advantageous for protein and peptide-based therapies, where achieving high bioavailability is essential for therapeutic effectiveness.
ODTs with improved bioavailability offer a promising solution for the delivery of high molecular weight drugs, addressing a critical need in the pharmaceutical industry. This innovative approach not only enhances the therapeutic effectiveness of protein and peptide-based medications but also opens up new possibilities for the development and delivery of advanced pharmaceutical treatments, positioning ODTs as a valuable and increasingly important segment of the pharmaceutical market. All of these factors are leading to orally disintegrating tablet market growth.
What is Restricting ODT Suppliers from Reaching Their Full Potential in the Market?
“High Cost of Orally Dissolving Tablets Limiting Adoption among Low-income Patient Groups”
High costs of ODTs present a significant challenge to the market's growth trajectory. The production costs of ODTs are notably higher compared to traditional tablets or capsules. As a result, the affordability of ODTs is a major concern for patients with limited budgets, which limits the accessibility and adoption of ODTs. This can particularly impact the demand for ODTs in lower-income countries with cost-sensitive healthcare environments.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Analysis
The market in Chile is forecasted to expand at a CAGR of 9.9% from 2024 to 2034. The country is evaluated to occupy an orally disintegrating tablet market share of 21.5% in Latin America by 2034.
Which Factors are Making the United States a Profit Hub for ODT Suppliers?
“Growing Need for Pediatric and Geriatric Formulations and Patient-friendly Dosage Forms”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 7.47 Billion |
| Growth Rate (2024 to 2034) | 11.3% CAGR |
| Projected Value (2034F) | US$ 21.78 Billion |
The market for orally disintegrating tablets in the United States is being driven by rising demand for pediatric and geriatric formulations, as well as the need for patient-friendly dosage forms for people who have difficulty swallowing or are averse to traditional tablets. The rising prevalence of chronic diseases, such as cardiovascular disorders, mental health conditions, and allergies, is driving the development of orally disintegrating tablets in a variety of therapeutic areas across the country.
Will Focus on Innovation in Drug Formulations Push Sales of ODTs in Brazil?
“Improvements in Taste and Stability of ODTs Enhancing Patient Acceptance and Compliance”
| Attribute | Brazil |
|---|---|
| Market Value (2024E) | US$ 397 Million |
| Growth Rate (2024 to 2034) | 9.8% CAGR |
| Projected Value (2034F) | US$ 1.01 Billion |
Taste-masking techniques, super disintegrants, and freeze-drying technology are examples of technological advancements in formulation and manufacturing processes that improve the palatability, stability, and disintegration properties of ODTs. These advancements are boosting patient acceptance and compliance in Brazil. Strategic collaborations between pharmaceutical companies and contract manufacturing organizations (CMOs) are facilitating the development and commercialization of innovative drug formulations, which is one of the key orally disintegrating tablet market trends in the country.
Category-wise Insights
Based on distribution channel, the hospital pharmacy segment is evaluated to expand at a noteworthy CAGR of 12.7% from 2024 to 2034. With rising healthcare spending worldwide, there is a parallel increase in demand for pharmaceuticals, especially within hospital settings where a wide range of medical conditions are treated.
Which Drug Class Accounts for Significant Revenue Generation?
“Rising Sales of Orally Disintegrating Anti-Psychotics to Improve Patient Compliance”
| Attribute | Anti-Psychotics |
|---|---|
| Segment Value (2024E) | US$ 4.72 Billion |
| Growth Rate (2024 to 2034) | 12.8% CAGR |
| Projected Value (2034F) | US$ 15.76 Billion |
Anti-psychotics help reduce psychotic symptoms such as delusions and hallucinations including paranoia and hearing voices, reducing anxiety and stress. The availability of anti-psychotics in the ODT form enhances convenience for patients, thus driving patient compliance.
Why are ODTs Considered Valuable in the Management of CNS Symptoms?
“Orally Disintegrating Tablets Playing Crucial Role in Promoting Faster Healing”
| Attribute | CNS Disease |
|---|---|
| Segment Value (2024E) | US$ 14.15 Billion |
| Growth Rate (2024 to 2034) | 12.6% CAGR |
| Projected Value (2034F) | US$ 46.17 Billion |
CNS disease includes a broad spectrum of diseases including brain and spinal cord. Orally disintegrating tablets often help in reducing symptoms and pains in such diseases and help the patient to heal faster.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
The market for orally disintegrating tablets (ODTs) is extremely competitive, with several established and emerging players vying for market share.
Companies engage in the research, development, and commercialization of ODTs and other pharmaceutical products.
Product innovation, strategic partnerships and collaborations, mergers and acquisitions, and geographical expansion are some of the key strategies used by these players to maintain and grow their market share. Key players in the orally disintegrating tablet market are adapting themselves to the evolving market trends such as oral antivirals and oral solid dosage contracts.
Fact.MR provides detailed information about the price points of key orally disintegrating tablet manufacturers positioned across the world, sales growth, production capacity, and speculative technological expansion in this new market report.
Key Segments of OTD Market Research
-
By Drug Class :
- Anti-Psychotics
- Anti-Epileptics
- CNS Stimulants
- Anxiolytics
- Anti-Parkinsonian Drugs
- Anti-Hypertensives
- NSAIDs
- Anti-Allergy Drugs
- Proton Pump Inhibitors
- Others
-
By Disease Indication :
- CNS Disease
- GI Disease
- CVS Disorders
- Allergy
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
-
By Region :
- North America
- Latin America
- Eastern Europe
- Western Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. Drug Class 6.2. Disease Indication 6.3. Distribution Channel 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class 7.1. Anti-Psychotics 7.2. Anti-Epileptics 7.3. CNS Stimulants 7.4. Anxiolytics 7.5. Anti-Parkinsonian Drugs 7.6. Anti-Hypertensives 7.7. NSAIDs 7.8. Anti-Allergy Drugs 7.9. Proton Pump Inhibitors 7.10. Others 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Disease Indication 8.1. CNS Disease 8.2. GI Disease 8.3. CVS Disorders 8.4. Allergy 8.5. Others 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel 9.1. Hospital Pharmacies 9.2. Retail Pharmacies 9.3. Drug Stores 9.4. Online Pharmacies 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Eastern Europe 10.5. East Asia 10.6. South Asia & Pacific 10.7. Middle East & Africa 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Sales Forecast 2024 to 2034 by Drug Class, Disease Indication, Distribution Channel, and Region for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Johnson & Johnson Services Inc 20.2. Teva Pharmaceutical Industries Ltd. 20.3. Sun Pharmaceutical Industries Ltd. 20.4. Takeda Pharmaceutical Company Limited 20.5. Eli Lily and Company 20.6. Dr. Reddy’s Laboratories Ltd 20.7. Mylan N.V. 20.8. Bausch Health 20.9. GlaxoSmithKline Plc 20.10. Merck & Co Inc. 20.11. AstraZeneca 20.12. Bayer AG 20.13. F Hoffman-La Roche Ltd. 21. Assumptions and Acronyms Drug Classd 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Disease Indication, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Disease Indication, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Disease Indication, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Disease Indication, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Disease Indication, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Disease Indication, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 28: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 29: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Disease Indication, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Disease Indication, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Disease Indication, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 37: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 41: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 42: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 43: Western Europe Market Value (US$ Mn) Analysis, by Disease Indication, 2019 to 2023
Table 44: Western Europe Market Value (US$ Mn) Analysis, by Disease Indication, 2024 to 2034
Table 45: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Disease Indication, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 49: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 50: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 51: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 52: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 53: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 54: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 55: Eastern Europe Market Value (US$ Mn) Analysis, by Disease Indication, 2019 to 2023
Table 56: Eastern Europe Market Value (US$ Mn) Analysis, by Disease Indication, 2024 to 2034
Table 57: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Disease Indication, 2024 to 2034
Table 58: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 59: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 60: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 61: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 65: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 66: East Asia Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 67: East Asia Market Value (US$ Mn) Analysis, by Disease Indication, 2019 to 2023
Table 68: East Asia Market Value (US$ Mn) Analysis, by Disease Indication, 2024 to 2034
Table 69: East Asia Market Value (US$ Mn) Opportunity Analysis, by Disease Indication, 2024 to 2034
Table 70: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 71: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 72: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 73: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 74: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 75: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 76: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 77: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 78: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 79: South Asia & Pacific Market Value (US$ Mn) Analysis, by Disease Indication, 2019 to 2023
Table 80: South Asia & Pacific Market Value (US$ Mn) Analysis, by Disease Indication, 2024 to 2034
Table 81: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Disease Indication, 2024 to 2034
Table 82: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 83: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 84: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 85: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 86: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 88: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 89: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 90: MEA Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 91: MEA Market Value (US$ Mn) Analysis, by Disease Indication, 2019 to 2023
Table 92: MEA Market Value (US$ Mn) Analysis, by Disease Indication, 2024 to 2034
Table 93: MEA Market Value (US$ Mn) Opportunity Analysis, by Disease Indication, 2024 to 2034
Table 94: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 95: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Disease Indication, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Disease Indication, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 20: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 21: North America Market Share Analysis by Country, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Disease Indication, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Disease Indication, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 36: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 37: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 40: Latin America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 41: Latin America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 42: Latin America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 43: Latin America Market Share and BPS Analysis by Disease Indication, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projections by Disease Indication, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 50: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 51: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 52: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 53: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 54: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 55: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 56: Western Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 57: Western Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 58: Western Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 59: Western Europe Market Share and BPS Analysis by Disease Indication, 2024 & 2034
Figure 60: Western Europe Market Y-o-Y Growth Projections by Disease Indication, 2024 to 2034
Figure 61: Western Europe Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 62: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 66: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 70: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 71: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: Eastern Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 74: Eastern Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 76: Eastern Europe Market Share and BPS Analysis by Disease Indication, 2024 & 2034
Figure 77: Eastern Europe Market Y-o-Y Growth Projections by Disease Indication, 2024 to 2034
Figure 78: Eastern Europe Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 79: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 80: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 81: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 82: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 83: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 84: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 85: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 86: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 87: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 88: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 89: East Asia Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 90: East Asia Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 91: East Asia Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 92: East Asia Market Share and BPS Analysis by Disease Indication, 2024 & 2034
Figure 93: East Asia Market Y-o-Y Growth Projections by Disease Indication, 2024 to 2034
Figure 94: East Asia Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 95: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 96: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 97: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 98: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 99: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 100: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 101: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 102: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 103: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 104: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 105: South Asia & Pacific Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 106: South Asia & Pacific Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 107: South Asia & Pacific Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 108: South Asia & Pacific Market Share and BPS Analysis by Disease Indication, 2024 & 2034
Figure 109: South Asia & Pacific Market Y-o-Y Growth Projections by Disease Indication, 2024 to 2034
Figure 110: South Asia & Pacific Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 111: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 112: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 113: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 114: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 115: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 116: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 117: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 118: MEA Market Share Analysis by Country, 2024 & 2034
Figure 119: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 120: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 121: MEA Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 122: MEA Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 123: MEA Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 124: MEA Market Share and BPS Analysis by Disease Indication, 2024 & 2034
Figure 125: MEA Market Y-o-Y Growth Projections by Disease Indication, 2024 to 2034
Figure 126: MEA Market Attractiveness Analysis by Disease Indication, 2024 to 2034
Figure 127: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 128: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 129: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the orally disintegrating tablet market in 2024?
The global market for orally disintegrating tablets is estimated at US$ 24.45 billion in 2024.
What is the estimated CAGR for the orally disintegrating tablet market?
The orally disintegrating tablet market is foreseen to advance at a CAGR of 11.5% between 2024 and 2034.
What portion of the North American market does Canada occupy?
Canada is forecasted to hold 12.2% share of the North American market by 2034.
What is the demand projection for ODTs for 2034?
Worldwide revenue from the sales of orally disintegrating tablets is projected to reach US$ 72.68 billion by 2034.
How fast is the market projected to expand in Chile?
The market in Chile is forecasted to expand at 9.9% CAGR through 2034.
Who are the leading manufacturers of OTDs?
Leading market players are Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.
What are the estimated sales of anxiolytic drug classes?
Revenue from anxiolytic drug classes is estimated to reach US$ 2.5 billion in 2024.
Orally Disintegrating Tablet Market